Avantor Results Presentation Deck

Acquisition of Ritter GmbH will enhance Avantor's proprietary consumables portfolio Ritter highlights Fast-growing, technology leader in high-precision consumables: robotic tips, microplates, cartridges Products engineered to exacting standards Expands proprietary consumables offering for high- growth lab automation workflows: PCR, NGS, Cell- based assays Leverages Avantor's channel and deep customer relationships to broaden Ritter's OEM customer base Transaction details Purchase price Revenue Closing EPS Financing ROIC €890M¹ cash up-front consideration, plus potential €300M earn-outs through 2023 >€225M FY21 estimated revenue Expected close in early Q3 2021 Expected accretion to adjusted EPS in 2021 Funded by cash on hand and term loans, <4X expected leverage at close LDD² by year 5 avantor M ~$7B Projected TAM³ in 2025 Market dynamics HSD²% Long-term market growth END MARKETS Invitro Diagnostic Tests Molecular assays testing genetic materials within cells and non-molecular assays testing viral antigens or antibodies Life Sciences Tests Testing related to clinical trials and drug discovery In Vitro Diagnostic Tests (COVID-related) Lab-based diagnostic tests and Point of Care (POC) screening tests 1. Estimated equity value, subject to final adjustments at closing; excludes assumed net indebtedness 2. LDD = Low Double Digit, HSD = High Single Digit 3. TAM = Total Addressable Market - Source: Kalorama, Allied Market Research, Markets and Markets, Expert Interviews % of Projected TAM³ in 2021 ~60% -30% ~10% 4

View entire presentation